title: Thyroid function should be monitored following radiotherapy to the low neck.
abstract: The purpose of this study was to determine whether the incidence of hypothyroidism following radiotherapy (RT) to the low neck is high enough to justify the routine monitoring of thyroid function in asymptomatic patients. A retrospective study of 504 patients with head and neck cancer whose RT fields included the thyroid gland was conducted. Patients were treated either with definitive or postoperative RT. Hypothyroidism was defined as a thyroid stimulating hormone (TSH) level > or =4.5 mIU/L, regardless of whether the patient had clinical symptoms. Of the 504 total patients, 206 had a serum TSH level checked at some point posttreatment. If we assume that patients who had no data did not have hypothyroidism, the actuarial freedom from hypothyroidism in the entire group was 78% at 5 years and 51% at 10 years. Of the 206 patients who had a documented posttreatment TSH, the actuarial freedom from hypothyroidism was 58% at 5 years and 26% at 10 years. Univariate analysis and multivariate analysis confirmed treatment modality to be a significant predictive factor. Definitive initial surgery that removed part of the thyroid gland increased the risk of developing hypothyroidism. Overall stage was also predictive on multivariate analysis. Head and neck irradiation results in biochemical hypothyroidism in at least 50% of patients. Thyroid function should be tested on a regular basis following RT to the low-neck region. Serum TSH should be checked every 6 months for the first 5 years and yearly thereafter. Thyroid hormone replacement should be initiated in any patient with a TSH of more than 4.5 mIU/L.
authors.affiliation: Department of Radiation Oncology, University of Florida, College of Medicine, Gainesville, FL 32610-0385, USA.
authors.forename: Allie
authors.initials: A
authors.lastname: Garcia-Serra
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Amdur
authors.forename: Christopher G
authors.initials: CG
authors.lastname: Morris
authors.forename: Ernest
authors.initials: E
authors.lastname: Mazzaferri
authors.forename: William M
authors.initials: WM
authors.lastname: Mendenhall
mesh_terms: D000206:Actuarial Analysis; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers; D003131:Combined Modality Therapy; D005260:Female; D005431:Florida / Q000453:epidemiology; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D007012:Hypopharyngeal Neoplasms / Q000532:radiotherapy; D007037:Hypothyroidism / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D007822:Laryngeal Neoplasms / Q000532:radiotherapy / Q000601:surgery; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection; D009959:Oropharyngeal Neoplasms / Q000532:radiotherapy; D011183:Postoperative Complications / Q000453:epidemiology / Q000209:etiology; D011832:Radiation Injuries / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D011878:Radiotherapy / Q000009:adverse effects*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013961:Thyroid Gland / Q000528:radiation effects*; D013972:Thyrotropin / Q000097:blood; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D013972:Thyrotropin